Once dismissed as “junk” DNA, ancient viruses embedded in the human genome play a key role in early human development, ...

Q2 2025 Earnings Call Transcript August 7, 2025 Insmed Incorporated misses on earnings expectations. Reported EPS is $-1.7 ...

The FDA approved labeling changes for elivaldogene autotemcel (eli-cel; Skysona), a one-time gene therapy for patients with early, active cerebral adrenoleukodystrophy (CALD), to reflect new safety ...

Neuroblastoma can be a particularly insidious cancer. In about half of all cases, tumors regress, even without therapy. In ...

After telegraphing an investigation in November, the FDA has moved to restrict the use of bluebird bio’s gene therapy Skysona ...

After a strong launch for its cancer gene therapy, Ferring Pharmaceuticals is setting the stage for long-term growth.

In medicine and biotechnology, the ability to evolve proteins with new or improved functions is crucial, but current methods ...

Net loss per share (GAAP) was $0.62, but remained negative as the company continues to invest heavily in research and development. The pivotal Phase 2 trial for Danon disease was placed on clinical ...

Sarepta Therapeutics Inc.’s shares soared after the US biotech reported revenue that beat estimates, which analysts ...

The fundraise will help advance a cancer therapy that’s already shown early promise in people whose cancers haven’t responded ...

Sarepta did not hold an investor call for its second-quarter earnings report or provide an updated full-year revenue outlook.